ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $19.38.

A number of brokerages have issued reports on PRQR. Zacks Investment Research raised shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday, August 30th. ValuEngine raised shares of ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a research note on Tuesday, September 26th. Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics N.V. in a research note on Sunday, September 17th. Finally, JMP Securities increased their price objective on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th.

Shares of ProQR Therapeutics N.V. (PRQR) opened at 4.60 on Wednesday. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70. The firm’s market capitalization is $110.88 million. The firm’s 50-day moving average price is $5.20 and its 200 day moving average price is $5.05.

COPYRIGHT VIOLATION NOTICE: “ProQR Therapeutics N.V. (PRQR) Given Consensus Recommendation of “Buy” by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/04/proqr-therapeutics-n-v-prqr-given-consensus-recommendation-of-buy-by-brokerages.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new stake in ProQR Therapeutics N.V. during the second quarter worth approximately $2,028,000. Artal Group S.A. raised its position in shares of ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after purchasing an additional 100,000 shares during the period. Finally, Redmile Group LLC raised its position in shares of ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after purchasing an additional 43,050 shares during the period. Hedge funds and other institutional investors own 35.93% of the company’s stock.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.